GET DAILY SIGNALSCoherus BioSciences (CHRS) Shares Drop -42.6% Over 30 Days on Cash and Guidance Concerns
Key Takeaways
- CHRS has fallen roughly 42.6% over the last 30 days, trading near $0.59 compared with a closing price of $1.03 about 30 days earlier.
- The decline accelerated after third-quarter 2026 results missed revenue consensus and management cut full-year LOQTORZI guidance.
- Coherus disclosed less than 12 months of cash runway in its quarterly filing, including going-concern language that weighed heavily on the shares.
- Management announced a roughly 30% workforce reduction and narrowed pipeline focus to esophageal cancer to lower core cash burn.
- Encouraging interim Tagmokitug data in esophageal cancer in late October was overshadowed by balance-sheet and financing concerns.
- Over the trailing three months, CHRS has declined roughly 51% from about $1.21, reflecting a sustained downtrend rather than a single-day move.
- For additional detail, investors can explore Coherus Price Targets, Earnings, and Forecast pages to review data and expectations.
- Traders seeking data-driven signals can also explore Trending AI Robots for additional tools.
Coherus BioSciences (CHRS) Company Overview and Market Position
Coherus BioSciences, Inc., which now does business as Coherus Oncology, is a commercial-stage biopharmaceutical company focused on oncology. Its approved product is LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor cleared by the FDA for use in combination with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma. The company also maintains a clinical pipeline led by Tagmokitug, an anti-CCR8 antibody, and Casdozokitug, an IL-27 antagonist. Coherus was historically a biosimilars developer behind products such as UDENYCA, CIMERLI, and YUSIMRY, but it has divested those franchises to concentrate on immuno-oncology. Investors track CHRS for LOQTORZI revenue growth, pipeline readouts, and its path toward financial self-sufficiency, while also weighing the company's small-cap profile, cash position, and financing risk. I checked some peer comparisons using Tickeron’s AI Screener to see how the stock stacks up in the sector.
Coherus BioSciences (CHRS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CHRS declined roughly 42.6%, falling from a closing price of about $1.03 to the low-$0.59 level. The move was not linear: the stock dropped sharply in late October after the release of interim Tagmokitug clinical data and again in November after third-quarter earnings. On October 29, the shares fell roughly 24.6% on volume well above average and reached a 52-week low near $0.81.
The quarterly picture is similarly negative. From a closing level of about $1.21 in early August, CHRS has lost roughly 51%, extending a multi-month decline that reflects both company-specific developments and broader pressure on sub-$1 small-cap biotech names. The stock's 52-week high sits well above current levels, underscoring how far sentiment has shifted. From what I see in the charts, this has been a steady erosion rather than an isolated event.
What Drove CHRS Stock Price in the Last 30 Days
Several verified catalysts shaped the 30-day move. On October 28, Coherus reported interim Tagmokitug clinical data in esophageal cancer, including a 75% overall response rate in the front-line setting. Despite the positive headline data, investors focused on the company's financing position, and the stock fell sharply the following session on unusually heavy volume. I also reviewed this using Tickeron’s AI Pattern Search Engine to confirm the volume spike pattern.
The larger catalyst came on November 9, when Coherus reported third-quarter 2026 results. Revenue of $14.27 million missed the consensus estimate of about $15.98 million, while non-GAAP loss per share was $0.20. LOQTORZI net sales grew 25% year over year to $14 million but rose only 3% sequentially. Management lowered full-year 2026 LOQTORZI guidance to $54 million to $57 million and disclosed a cash runway of less than 12 months, accompanied by going-concern language in the filing. The company also announced a roughly 30% headcount reduction and a narrowed pipeline focus on esophageal cancer. The shares fell about 21.6% on November 10 in response.
What Drove CHRS Stock Performance Over the Last Quarter
The quarterly decline reflects a longer narrative of a company transitioning to a pure-play oncology business while contending with a shrinking cash position. Cash, equivalents, and investments declined from roughly $172 million at the end of 2025 to about $83.6 million by the end of the third quarter of 2026. Second-quarter results had also missed revenue expectations, and the company refinanced a term loan during the period. A UDENYCA divestiture milestone that management had previously described as achievable was narrowly missed, adding uncertainty around a potential cash source. These balance-sheet pressures, combined with slower-than-targeted LOQTORZI sequential growth, drove a steady de-rating of the shares across the quarter.
CHRS Stock Forecast Drivers: What Investors Should Watch Next
Going forward, investors will likely monitor LOQTORZI's fourth-quarter trajectory against management's roughly $15 million quarterly target and the longer-term goal of reaching a $25 million to $30 million quarterly revenue run rate needed to cover core costs. The Tagmokitug esophageal cancer development path, including potential regulatory discussions and any accelerated-approval plans, is another key catalyst. Financing remains a central risk, with potential levers including equity or debt raises, ex-US partnering for Tagmokitug, and the disputed UDENYCA milestone payments. Macroeconomic conditions, sector sentiment toward micro-cap biotechnology, and any further analyst actions may also influence trading. These are factual considerations rather than recommendations or predictions. I’m watching this closely as the next earnings cycle approaches.
AI Tools in My Research Workflow
In my own analysis, I often turn to Tickeron’s AI Trading Bots to see how automated strategies are performing on names like this. The platform offers a range of bots with different approaches, which can provide additional data-driven perspectives alongside fundamental research. This helps supplement my review of price action and company filings without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
CHRS's Stochastic Oscillator sits in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CHRS's RSI Indicator exited the oversold zone, 29 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 44 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.498). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology
Advertisement